derma and cardiac drugs

India's pharmaceutical retail market rebounded in November with double-digit growth, driven by increased demand for dermatological and cardiac medications. Respiratory issues, exacerbated by pollution, boosted Foracort sales to Rs 82 crore. Both acute and chronic medications saw 11% growth, and industry volumes rose by 3.5%. Analysts predict continued growth in 2025, fueled by price increases and new drug launches.

The revision in the National List of Essential Medicines (NLEM) by the government last week is expected to translate into savings of 10-20% for patients at the therapy level on widely used antibiotics, anti-infectives, cardiac and respiratory medicines.

The national pharma policy, once implemented, would lead to a value erosion of around 2% of the overall pharmaceutical market.

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant launches in cardiac, anti-diabetic, and vitamins sectors, highlighting prevailing health patterns in India.

Scanty rainfall in the country over the last couple of weeks is not making only policy-makers and farmers a worried lot. It has also led to a slackening in June sales of anti-infective and respiratory medicines — therapies which traditionally show a strong double-digit growth during the monsoon season.

Domestic organized pharma retail market crossed Rs 90,000 crore for the first time ever in cumulative sales, driven by a huge growth in sales of anti-diabetic drugs, dermatology and urology medicines.

Gujarat's pharmaceuticals market grew by 19% from June 2022 to May 2024. Rise in pollution and allergens contributed to increased respiratory illnesses. Seasonal changes and flu cases led to a spike in allergy cases and demand for respiratory medicines.

New Delhi, Aug 13 () Drug firm Alkem Laboratories is looking to tap domestic as well as international markets for growth going forward, the company has said.

Scanty rainfall in the country over the last couple of weeks is not making only policy-makers and farmers a worried lot.

Mumbai, Aug 11 () Indian pharmaceutical drug formulation market grew 9.5 per cent to Rs 9,125 crore in July with Indoco Remedies leading the race with 27.8 per cent growth followed by Aristo and Hetero, according to pharmaceutical market research data compiled by AIOCD AWACS.

Domestic pharma retail market bounced back with a substantial growth of 8.4% yoy (year-on-year) in December, after a weak performance during the year, led by a higher number of prescriptions, OPD (outpatient department) visits, and increased marketing push by drug companies.